Peptide-containing liquid formulation and method for producing the same
A stable peptide-containing liquid formulation is achieved using buffer solutions at pH 4 to 6, addressing stability issues and enabling room-temperature storage and use, thus simplifying handling and manufacturing.
Patent Information
- Application Number
- JP2026524718
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2023-10-27
- Publication Date
- 2026-11-19
AI Technical Summary
Formulating peptides with the amino acid sequence of SEQ ID NO: 1 or pharmaceutically acceptable salts thereof in a stable liquid form is challenging due to their electrochemical properties, which are unpredictable and difficult to stabilize.
A peptide-containing liquid formulation is developed using a buffer solution with a pH of 4 to 6, comprising phosphate, succinate, or acetate buffer solutions, along with pH adjustment and optional additives like sodium chloride or sorbitol, to maintain stability and suppress impurity generation.
The formulation ensures stability of peptides in liquid form at room temperature, eliminating the need for freeze-drying, facilitating convenient storage, distribution, and easy use, while maintaining purity above 95% and impurity content below 3%.
Smart Images

Figure 2026539052000001_ABST
Abstract
Description
TECHNICAL FIELD
[0001] The present invention relates to a peptide-containing liquid formulation comprising, as an active ingredient, a peptide comprising the amino acid sequence of SEQ ID NO: 1 or a pharmaceutically acceptable salt thereof, and a method for producing the same. More specifically, the present invention relates to a stable peptide-containing liquid formulation comprising, as an active ingredient, a peptide comprising the amino acid sequence of SEQ ID NO: 1 or a pharmaceutically acceptable salt thereof, and a method for producing the same. BACKGROUND ART
[0002] Development of pharmaceuticals that use not only conventional compounds but also specific peptides or pharmaceutically acceptable salts thereof as active ingredients is in progress (see International Publication No. 2012 / 002668 A2). This peptide can also be chemically synthesized, and can be regarded as a type of compound. However, peptides have properties such as electrochemical characteristics that differ from those of compounds that have been developed as conventional pharmaceuticals, and it is not easy to predict such properties. In particular, unexpected difficulties may be encountered in the process of formulating peptides.
[0003] The present inventors encountered unexpected difficulties in the formulation process of such peptides, and completed the present invention in the course of overcoming the difficulties. PRIOR ART DOCUMENTS PATENT DOCUMENTS
[0004] PATENT DOCUMENT 1 International Publication No. 2012 / 002668 A2, Jan. 5, 2012, Specification SUMMARY OF THE INVENTION PROBLEMS TO BE SOLVED BY THE INVENTION
[0005] One problem to be solved by the present invention is to provide a stable peptide-containing liquid formulation comprising, as an active ingredient, a peptide comprising the amino acid sequence of SEQ ID NO: 1 or a pharmaceutically acceptable salt thereof.
[0006] Another problem that the present invention aims to solve is to provide a method for producing a stable peptide-containing liquid formulation that contains a peptide or a pharmaceutically acceptable salt thereof containing the amino acid sequence of SEQ ID NO: 1 as an active ingredient.
[0007] The problems that this invention aims to solve are not limited to those described above, and other problems not mentioned will be clearly understood by those skilled in the art from the following description. [Means for solving the problem]
[0008] The present invention provides a peptide-containing liquid formulation comprising an active ingredient and a buffer solution, wherein the active ingredient is a peptide containing the amino acid sequence of SEQ ID NO: 1 or a pharmaceutically acceptable salt thereof, and the buffer solution is a phosphate buffer solution, a succinate buffer solution, or an acetate buffer solution, with a pH of 4 to 6.
[0009] Furthermore, the present invention provides a method for producing a peptide-containing liquid formulation comprising (A) a buffer solution preparation step of preparing a buffer solution containing an active ingredient, and (B) a pH adjustment step of adjusting the pH of the buffer solution containing the active ingredient to 4 to 6, wherein the active ingredient is a peptide containing the amino acid sequence of SEQ ID NO: 1 or a pharmaceutically acceptable salt thereof, and the buffer solution is a phosphate buffer solution, a succinate buffer solution, or an acetate buffer solution. [Effects of the Invention]
[0010] According to the present invention, a peptide containing the amino acid sequence of SEQ ID NO: 1, or a pharmaceutically acceptable salt thereof, can be stably formulated even in liquid form. Furthermore, since the formulation of the present invention ensures stability even in liquid form at room temperature, there is no need to take a freeze-dried form, resulting in convenient storage and distribution, as well as ease of manufacture and use. [Brief explanation of the drawing]
[0011] [Figure 1]Figure 1 is a flowchart illustrating one embodiment of the present invention. [Modes for carrying out the invention]
[0012] The present invention will be described in more detail below with reference to examples and manufacturing examples, but the following examples and manufacturing examples are merely illustrative and do not limit the present invention.
[0013] A peptide-containing liquid formulation according to one embodiment of the present invention comprises an active ingredient and a buffer solution, and has a pH of 4 to 6.
[0014] The active ingredient is a peptide containing the amino acid sequence of Sequence ID No. 1 (ELHLD) or a pharmaceutically acceptable salt thereof. In the amino acid sequence, E represents glutamic acid (Glu), L represents leucine (Leu), H represents histidine (His), and D represents aspartate (Asp). While L, D, and DL forms exist for the amino acids that make up the peptide, the amino acids that make up the peptide of the present invention include all of these. Examples of salts include hydrochloride, sulfate, phosphate, acetate, trifluoroacetate, citrate, tartrate, succinate, lactate, maleate, fumarate, oxalate, methanesulfonate, p-toluenesulfonate, sodium salt, potassium salt, magnesium salt, or calcium salt. The trifluoroacetate may also be ditrifluoroacetate (2TFA). Specifically, the active ingredient may preferably be a trifluoroacetate of a peptide consisting of the amino acid sequence of SEQ ID NO: 1, and more preferably a ditrifluoroacetate of a peptide consisting of the amino acid sequence of SEQ ID NO: 1.
[0015] Needless to say, regarding the active ingredients, one can refer to the information described in International Publication No. 2012 / 002668 A2 (January 5, 2012). For example, the active ingredients may exhibit therapeutic and / or preventive effects on cartilage damage and / or arthritis (including osteoarthritis), and the active ingredients or preparations containing them may be for the treatment and / or prevention of cartilage damage and / or arthritis (including osteoarthritis). The treatment and / or prevention may be by one or more selected from cartilage tissue regeneration, inhibition of the expression of cartilage matrix-degrading enzymes, and inhibition of ossification of cartilage tissue, and arthritis includes joint diseases involving degeneration of cartilage and subchondral bone.
[0016] The dosage for animals, including humans (including mammals), is 150 μg / day to 1 mg / day, preferably 0.5 mg / day to 1 mg / day, based on the active ingredient, when administered parenterally. The oral dosage is 1.2 to 1.5 times the parenteral dosage. The active ingredient or preparations containing it are administered parenterally, for example, by local injection (intra-articular injection), intravenous or subcutaneous injection, or nasal administration. In some cases, it may also be administered orally.
[0017] The active ingredient may be present in an amount of 0.05 to 1% by weight relative to the total weight of the preparation.
[0018] A buffer solution is a solution containing bufferable components. Here, buffer solutions include phosphate buffer solution, succinate buffer solution, or acetate buffer solution.
[0019] A phosphate buffer solution may be formed from phosphoric acid, or it may be formed by applying a buffering agent of phosphoric acid origin (e.g., monosodium phosphate, disodium phosphate, etc.).
[0020] Furthermore, the acetic acid buffer solution may be formed from acetic acid, or by applying a buffering agent derived from acetic acid (e.g., sodium acetate, acetic acid, etc.).
[0021] Furthermore, the succinate buffer solution is formed originating from succinic acid, and may be formed by applying a buffering agent derived from succinic acid (e.g., sodium succinate, succinic acid, etc.).
[0022] The phosphate buffer solution, succinate buffer solution, or acetate buffer solution, based on phosphate, succinate, or acetate, relative to 100 parts by weight of the active ingredient, may be contained in an amount of preferably 1 to 1000 parts by weight, more preferably 5 to 700 parts by weight, and even more preferably 10 to 500 parts by weight, respectively.
[0023] When the formulation according to one embodiment of the present invention contains such a buffer solution and has a pH of 4 to 6, the active ingredient can exhibit particularly good stability in a liquid state.
[0024] Here, "stable" means that the content of impurities (related substances) that are the pyro-form of the active ingredient is 3% or less. Also, preferably, in the formulation according to one embodiment of the present invention, the purity of the active ingredient may be 95% or higher. In the process of completing the present invention, the generation of pyro-form impurities (related substances) of the active ingredient was discovered, and the present invention makes it possible to suppress such generation. The amount of impurities (related substances) present can be measured by HPLC analysis. The change in the amount of related substances can be calculated as the sum of the area ratios of the total amount of related substances contained in the formulation to be analyzed. According to the present invention, the generation of impurities (related substances) can be suppressed, and the liquid state can be maintained in a stable condition. In particular, since the stability in the liquid state is maintained even at normal temperature, the present invention eliminates the need to formulate the product in a lyophilized form. That is, there is no need for storage and distribution under refrigerated conditions, and the product can be easily used even in regions where refrigerated storage is not readily available. In on-site application, it is convenient because it does not require the step of liquefying the lyophilized product for use as an injection and can be used directly in its liquid state, and the manufacturing process is also easy because the lyophilization step can be omitted. Here, the normal temperature is preferably in the range of 5 to 40°C, more preferably 10 to 30°C, and even more preferably 23 to 27°C.
[0025] On the other hand, in one embodiment, the pH can be adjusted with a pH adjusting agent. The pH adjusting agent is not particularly limited as long as it can adjust the pH, but may be one or more selected from, for example, sodium hydroxide, potassium hydroxide, sodium bicarbonate, sodium carbonate, potassium bicarbonate, potassium carbonate, acetic acid, or hydrochloric acid. The pH adjusting agent may be preferably 1 to 1000 parts by weight, more preferably 5 to 700 parts by weight, and even more preferably 10 to 500 parts by weight, per 100 parts by weight of the active ingredient. If the amount is less than or more than this range, the formulation may become unstable.
[0026] Furthermore, a formulation according to one embodiment may further contain pharmaceutically acceptable additives. The additives may be one or more selected from, for example, sodium chloride, sorbitol, or glycine. The additives are included in a pharmaceutically acceptable amount, preferably 1 to 10,000 parts by weight, more preferably 100 to 8,000 parts by weight, and even more preferably 500 to 6,000 parts by weight, per 100 parts by weight of the active ingredient.
[0027] The addition of this additive makes the formulation more stable.
[0028] The additives can be used in appropriate combinations depending on the type of buffer solution. Specifically, in one embodiment of the present invention, the buffer solution is an acetate buffer solution, the additive is one or more selected from sodium chloride or sorbitol, and the pH is 4 to 5.5; the buffer solution is a succinic acid buffer solution, the additive is glycine, and the pH is 5 to 6; or the buffer solution is a phosphate buffer solution, the additive is one or more selected from sodium chloride or sorbitol, and the pH is 5.5 to 6.
[0029] A liquid formulation according to one embodiment of the present invention can also be manufactured by a manufacturing method according to one embodiment of the present invention. The method for manufacturing a peptide-containing liquid formulation according to one embodiment of the present invention will be described in more detail below with reference to Figure 1.
[0030] Figure 1 is a flowchart illustrating one embodiment of the present invention. As shown in Figure 1, a method for producing a peptide-containing liquid formulation according to one embodiment of the present invention includes (A) a step of preparing an active ingredient-containing buffer solution, and (B) a step of adjusting the pH.
[0031] (A) The step of preparing a buffer solution containing the active ingredient is the step of preparing a buffer solution containing the active ingredient. The active ingredient and the buffer solution are substantially identical to the formulation according to one embodiment of the present invention. However, the term "buffer solution" in step (A) means a solution containing components (e.g., buffering agents) that can form a buffer solution, regardless of whether or not they actually have buffering capacity. In other words, the buffer solution in step (A) is not limited to always exhibiting buffering capacity in all steps, as long as it corresponds to at least one component that imparts buffering capacity to the final liquid formulation.
[0032] The buffer solution may further contain additives, which are also substantially identical to those of the formulation according to one embodiment. Specifically, in step (A), the buffer solution is obtained by mixing an aqueous solution containing additives with a component capable of forming a buffer solution. The component capable of forming a buffer solution (e.g., a buffering agent) and the additive can be mixed in any order to form a mixture. For example, an aqueous solution containing a pharmaceutically effective amount of the component capable of forming a buffer solution (e.g., a buffering agent) may be prepared first, and then the additive may be added, or the additive may be dissolved in water, and then the component capable of forming a buffer solution (e.g., a buffering agent) may be added in a pharmaceutically effective amount. The buffering agent may be, for example, acetic acid, phosphoric acid, succinic acid, monopotassium phosphate, distocotassium phosphate, sodium acetate, distocodium phosphate, monosodium phosphate, and / or sodium succinate. In this case, the active ingredient can also be added to water and mixed with the additives and / or the component capable of forming a buffer solution, regardless of the order of addition. At this time, it is also possible to form a buffer solution by adding a strong base, such as a basicizing agent (e.g., sodium hydroxide), to a weak acid, such as a buffering agent. Furthermore, the pH can be adjusted before adding the active ingredient. pH adjustment can be carried out by adding a basicizing agent (e.g., sodium hydroxide) to water, and such a basicizing agent can also play a role in forming a buffer solution together with a weak acid.
[0033] (B) The pH adjustment step is to adjust the pH of the buffer solution containing the active ingredient to 4-6. The adjustment in step (B) can be performed using a pH adjusting agent, which is substantially identical to the formulation according to one embodiment of the present invention.
[0034] By following these steps, a stable peptide-containing liquid formulation according to one embodiment of the present invention can be manufactured.
[0035] Unless otherwise specified, the matters referred to in the formulations and manufacturing methods of the present invention shall apply equally to each other to the extent of their identity, provided that they do not contradict each other.
[0036] The following describes in more detail the manufacturing method and peptide according to one embodiment of the present invention, with reference to manufacturing examples and reference examples.
[0037] In the following manufacturing examples and reference examples, the highest grade reagents and materials available commercially were used, and unless otherwise specified, they were purchased from Sigma-Aldrich.
[0038] <Example> Production of a peptide-containing liquid formulation 1.1. Preparation of peptides produced by solid-phase peptide manufacturing method The trifluoroacetate (Glu-Leu-His-Leu-Asp·2 TFA) of a peptide with the amino acid sequence shown in Table 1 was prepared using a general solid-phase peptide manufacturing method. Specifically, H-Asp(OtBu)-2-ClTrt solid-phase resin (substitution rate: 0.63-0.67 mmol / g) was used as the starting material, and the peptide was prepared using the standard fluorenylmethyloxycarbonyl solid-phase peptide synthesis (Fmoc-SPPS) method. First, 125.0 g of the H-Asp(OtBu)-2-ClTrt peptide resin, the starting material, was placed in a thoroughly dried reactor, and N,N-dimethylformamide (DMF, 1250 ml, 10 mL / g resin) was added and stirred for 20 minutes to swell the resin. After that, the filtrate was filtered and discarded, and the resin was washed twice with N,N-dimethylformamide (DMF, 750 ml, 6 mL / g resin). In a separate reactor, Fmoc-Leu-OH (1.5 equivalents relative to the starting material) and hydroxybenzotriazole (HOBt, 1.5 equivalents relative to the starting material) were added, and N,N-dimethylformamide (DMF, 4.5 mL per gram of starting material) was added to dissolve them. Then, diisopropylethylamine (DIPEA, 1.5 equivalents relative to the starting material) was added. After cooling the reaction solution to 0-5°C, 3-[bis(dimethylamino)methyliumyl]-3H-benzotriazole-1-oxidehexafluorophosphate (HBTU, 1.5 equivalents relative to the starting material) was added to activate the carboxyl groups of the amino acids. Dichloromethane (1.5 mL per gram of starting material) was added to the reactor containing the starting material peptide resin, and while stirring, the activated amino acid (Fmoc-Leu-OH) derivative solution prepared in a separate reactor was gradually added, and the reaction mixture was stirred at a temperature of 10-30°C for 2 hours. The reaction was confirmed using the ninhydrin (Kaiser) test. After the reaction was complete, the peptide-resin was filtered and washed with the solvents N,N-dimethylformamide (DMF) and methyl t-butyl ether (MTBE), respectively. The peptide-resin solids were then washed twice again with N,N-dimethylformamide (DMF) (750 ml, 6 mL / g resin).Next, as part of the fluorenylmethyloxycarbonyl (Fmoc) deprotection reaction, the peptide resin was treated twice with a 5% piperidine mixed solution (v / v / w / v: 5% piperidine / 1.25% DBU / 1% HOBt / DMF) (750 ml, 6 mL / g resin, stirred for 10 minutes each time, then filtered) to carry out the deprotection reaction. After filtration, the filtered peptide resin was washed with N,N-dimethylformamide (DMF) twice, methyl t-butyl ether (MTBE) twice, and N,N-dimethylformamide (DMF) twice (60 mL / g resin for each solvent). The fluorenylmethyloxycarbonyl (Fmoc) deprotection reaction was confirmed by the ninhydrin (Kaiser) test. Coupling and fluorenylmethyloxycarbonyl (Fmoc) deprotection reactions with amino acid derivatives #3, #4, and #5 were carried out in the same manner as described above. Specifically, Fmoc-His(Trt)-OH was used in reaction #3, Fmoc-Leu-OH in reaction #4, and Fmoc-Glu(OtBu)-OH in reaction #5. By sequentially reacting the amino acids with the peptide resin, Fmoc-Glu(OtBu)1-Leu2-His(Trt)3-Leu4-Asp(OtBu)5-2-ClTrt peptide resin was synthesized. However, when introducing the amino acid Fmoc-His(Trt)-OH in reaction #3, N,N-dimethylformamide / dichloromethane (DCM / DMF) was used as the mixed solvent, and N-hydroxybenzotriazole / N,N,N-diisopropylcarbodiimide was used to activate the carboxyl group in the coupling reaction. The N-terminal fluorenylmethyloxycarbonyl (Fmoc) group of Fmoc-Glu(OtBu)1-Leu2-His(Trt)3-Leu4-Asp(OtBu)5-2-ClTrt peptide-resin was removed by adding a 5% piperidine mixed solvent (v / v / w / v: 5% piperidine / 1.25% DBU / 1% HOBt / DMF), stirring, filtering, and washing to synthesize H-Glu(OtBu)1-Leu2-His(Trt)3-Leu4-Asp(OtBu)5-2-ClTrt peptide-resin.
[0039] In a separate reactor, a mixed solution of trifluoroacetic acid / triisopropylsilane / dichloromethane (TFA / TIS / DCM: 55 / 5 / 40, v / v / v, 450 ml, 10 mL per gram of peptide resin) was added as a deprotecting group mixture solution, and the temperature was cooled to 0-5°C. The resulting peptide-resin was gradually added to the cooled solution while maintaining the reaction mixture temperature below 17°C (optimal temperature: 13.8-14.6°C). Subsequently, the reaction mixture was heated to 23-27°C and stirred at the same temperature for 90 minutes. The solid resin was filtered through a polytetrafluoroethylene (PTFE) filter, and the mixture was washed twice with trifluoroacetic acid (TFA) (1.0 mL per gram of peptide resin x 2 times) to collect all of the filtrate. The collected filtrate was then concentrated under reduced pressure at 30°C or below until its volume was 20-30%. To the concentrated residue, pre-cooled methyl t-butyl ether (MTBE) solvent (approximately 10 times the volume of concentration) was added to generate the crude peptide as a solid precipitate. The resulting solid precipitate was stirred at room temperature for 1 hour, filtered, and washed five times with cooled methyl t-butyl ether (MTBE) solvent (50% of the amount of MTBE used for precipitation). The filtered crude peptide was vacuum-dried at 24°C for approximately 30 hours to synthesize the ditrifluoroacetate (Glu-Leu-His-Leu-Asp·2TFA, 57.4 g) of the crude peptide having the amino acid sequence of SEQ ID NO: 1, with a deprotection peptide yield of 98.4% and HPLC purity of 86%. Subsequently, the ditrifluoroacetate of the crude peptide was separated by reverse-phase high-performance liquid chromatography using a purified water / acetonitrile developing solvent system containing 0.1% (v / v) trifluoroacetic acid. The purity (shown in Table 1, 97% or higher) and molecular weight of the purified peptide (Glu-Leu-His-Leu-Asp·2TFA) were confirmed using LC / MS. Purity and TFA equivalents were confirmed by HPLC, the amino acid sequence by LC / MS / MS, and the molecular weight by LC / MS. The results are shown in Table 1 below.
[0040] [Table 1]
[0041] 1.2. Preparation of buffer solution containing active ingredients and adjustment of pH 3600 ml of sterile water for injection and the buffers and additives shown in Table 2 were added to a thoroughly cleaned reactor and stirred at room temperature (25°C) for 10 minutes. Then, 1 M sodium hydroxide solution was gradually added dropwise to adjust the pH of the reaction solution to 5.5, and the mixture was stirred for 30 minutes. At the same temperature, 3.6 g of peptide salt (1-1) prepared in "1.1." was added, and the pH adjuster was gradually added dropwise to adjust the pH of the solution to the value shown in Table 2. The dissolved solution was filtered through a 0.2 microfilter and filled into vials or syringes.
[0042] [Table 2]
[0043] <Example> Manufacturing of peptide-containing liquid formulations A peptide-containing liquid formulation was prepared in the same manner as in the examples, except that the conditions for preparing the buffer solution containing the active ingredient and adjusting its pH were changed from those shown in Table 2 to those shown in Table 3.
[0044] [Table 3]
[0045] <Experimental Example> Stability Test Stability tests were conducted on the liquid formulations prepared in the examples and reference examples. Specifically, the examples and reference examples were stored in a storage chamber under accelerated storage conditions (40±2℃, RH=75±5%), and their purity and the content of related substances (pyro-impurities of the active ingredient) were confirmed by HPLC. The experimental results under accelerated storage conditions for 6 months are summarized in Table 4 below.
[0046] [Table 4]
[0047] As shown in Table 4, the liquid formulation of the present invention exhibits excellent stability. In particular, when no buffering agent and pH adjuster are applied, the pyro-impurity content is as high as 7.8%, but according to the present invention, the pyro-impurity content is low, demonstrating its superior effectiveness. Furthermore, in the reference example outside the pH range of 4 to 6, the pyro-impurity content exceeds 3% and the purity does not reach 95%, which falls outside the acceptable range for quality control. In contrast, all of the examples of the present invention satisfy the quality control standards (pyro-impurity of 3% or less, purity of 95% or more). Therefore, it has been confirmed that all of the examples of the present invention are stable liquid formulations that meet the quality control standards. Such effects are achieved when the buffer solution is a phosphate buffer solution, succinate buffer solution, or acetate buffer solution, and are more preferable when succinate buffer solution or acetate buffer solution is used.
[0048] Therefore, according to the present invention, peptides containing the amino acid sequence of SEQ ID NO: 1 or pharmaceutically acceptable salts thereof can be stably formulated even in liquid form. Furthermore, since the formulations of the present invention can maintain stability even in liquid form at room temperature, there is no need to take a lyophilized form, making storage and distribution convenient, and manufacturing and use easy. [Industrial applicability]
[0049] The present invention has the effect of stably formulating peptides containing the amino acid sequence of SEQ ID NO: 1, or pharmaceutically acceptable salts thereof, even in liquid form. Furthermore, since the formulations of the present invention maintain stability even in liquid form at room temperature, there is no need to take a freeze-dried form, resulting in convenient storage and distribution, and ease of manufacture and use. Therefore, the present invention has industrial applicability.
Claims
1. It contains an active ingredient and a buffer solution, The active ingredient is a peptide containing the amino acid sequence of SEQ ID NO: 1 or a pharmaceutically acceptable salt thereof. The buffer solution is a phosphate buffer solution, a succinate buffer solution, or an acetate buffer solution. A peptide-containing liquid formulation with a pH of 4-6.
2. The peptide-containing liquid formulation according to claim 1, further comprising one or more additives selected from sodium chloride, sorbitol, or glycine.
3. The peptide-containing liquid formulation according to claim 2, wherein the buffer solution is an acetate buffer solution, the additive is one or more selected from sodium chloride or sorbitol, and the pH is 4 to 5.
5.
4. The peptide-containing liquid formulation according to claim 2, wherein the buffer solution is succinate buffer solution, the additive is glycine, and the pH is 5 to 6.
5. The peptide-containing liquid formulation according to claim 2, wherein the buffer solution is a phosphate buffer solution, the additive is one or more selected from sodium chloride or sorbitol, and the pH is 5.5 to 6.
6. (A) A buffer solution preparation step in which an active ingredient is prepared, (B) A pH adjustment step of adjusting the pH of the buffer solution containing the active ingredient to 4 to 6, The active ingredient is a peptide containing the amino acid sequence of SEQ ID NO: 1 or a pharmaceutically acceptable salt thereof. A method for producing a peptide-containing liquid formulation, wherein the buffer solution is a phosphate buffer solution, a succinate buffer solution, or an acetate buffer solution.
Citation Information
Patent Citations
Novel peptide and use thereof
WO2012002668A2
